KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Non-Current Deffered Revenue (2019 - 2026)

Aquestive Therapeutics has reported Non-Current Deffered Revenue over the past 7 years, most recently at $19.4 million for Q4 2025.

  • For Q4 2025, Non-Current Deffered Revenue fell 3.07% year-over-year to $19.4 million; the TTM value through Dec 2025 reached $19.4 million, down 3.07%, while the annual FY2025 figure was $19.4 million, 3.07% down from the prior year.
  • Non-Current Deffered Revenue for Q4 2025 was $19.4 million at Aquestive Therapeutics, down from $19.7 million in the prior quarter.
  • Over five years, Non-Current Deffered Revenue peaked at $33.1 million in Q2 2023 and troughed at $4.7 million in Q1 2021.
  • A 5-year average of $20.3 million and a median of $19.8 million in 2025 define the central range for Non-Current Deffered Revenue.
  • Biggest five-year swings in Non-Current Deffered Revenue: skyrocketed 341.13% in 2022 and later plummeted 38.22% in 2025.
  • Year by year, Non-Current Deffered Revenue stood at $7.1 million in 2021, then skyrocketed by 341.13% to $31.4 million in 2022, then rose by 2.95% to $32.3 million in 2023, then crashed by 38.15% to $20.0 million in 2024, then decreased by 3.07% to $19.4 million in 2025.
  • Business Quant data shows Non-Current Deffered Revenue for AQST at $19.4 million in Q4 2025, $19.7 million in Q3 2025, and $19.9 million in Q2 2025.